Lebrikizumab in Moderate-to-severe Atopic Dermatitis

Study acronym: ADfind
StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 1 entry Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Study completion pushed from Jul 2027 to Jul 2028
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: details revised at 4 of 5 entries
    • Site details revised at 4 of 4 sites
  2. Re-verified, no change to tracked fieldsv5
  3. Primary and study completion dates: Jun 2027 to Jul 2027
    • Start date changed from estimate of Jul 2025 to Jul 2, 2025
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 2025 to Jul 2025
    • Site details revised at 4 of 4 sites
    v3
  5. Start date: Apr 2025 to Jun 2025
    • Primary and study completion dates: Mar 2027 to Jun 2027
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This research is studying a drug already approved for the treatment of atopic dermatitis (AD). This research collects health-related information and blood and skin samples to understand if the study drug, lebrikizumab, leads to long-term improvement in AD skin.
Trial Details
NCT Number NCT06906497
Lead Sponsor Johann E Gudjonsson MD PhD
Collaborators: Dermira, Inc., Almirall, S.A.
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov